Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn)

Adult Dosing .

Dosage forms:  INJ

Special Note

[formulation clarification]

Info: nonproprietary name = asparaginase erwinia chrysanthemi (recombinant)-rywn

[uses, dosing may vary]

Info: refer to institution protocols and pkg insert prior to prescribing for uses, premeds, and dosing incl. toxicity-related dose adjustments

ALL

[substitute for single calaspargase pegol dose]

Dose: 25 mg/m^2/dose IM q48h x11 doses; Alt: 25 mg/m^2/dose IM x1 on Monday morning, 25 mg/m^2/dose IM x1 on Wednesday morning, 50 mg/m^2/dose IM x1 on Friday afternoon x9 total doses; Info: for pts w/ E. coli-derived asparaginase hypersensitivity; part of multi-drug chemo

[substitute for single pegaspargase dose]

Dose: 25 mg/m^2/dose IM q48h x7 doses; Alt: 25 mg/m^2/dose IM x1 on Monday morning, 25 mg/m^2/dose IM x1 on Wednesday morning, 50 mg/m^2/dose IM x1 on Friday afternoon x6 total doses; Info: for pts w/ E. coli-derived asparaginase hypersensitivity; part of multi-drug chemo

lymphoblastic lymphoma

[substitute for single calaspargase pegol dose]

Dose: 25 mg/m^2/dose IM q48h x11 doses; Alt: 25 mg/m^2/dose IM x1 on Monday morning, 25 mg/m^2/dose IM x1 on Wednesday morning, 50 mg/m^2/dose IM x1 on Friday afternoon x9 total doses; Info: for pts w/ E. coli-derived asparaginase hypersensitivity; part of multi-drug chemo

[substitute for single pegaspargase dose]

Dose: 25 mg/m^2/dose IM q48h x7 doses; Alt: 25 mg/m^2/dose IM x1 on Monday morning, 25 mg/m^2/dose IM x1 on Wednesday morning, 50 mg/m^2/dose IM x1 on Friday afternoon x6 total doses; Info: for pts w/ E. coli-derived asparaginase hypersensitivity; part of multi-drug chemo

renal dosing

[not defined]

renal impairment: not defined

HD/PD: not defined

hepatic dosing

[not defined]

Peds Dosing .

Dosage forms:  INJ

Special Note

[formulation clarification]

Info: nonproprietary name = asparaginase erwinia chrysanthemi (recombinant)-rywn

[uses, dosing may vary]

Info: refer to institution protocols and pkg insert prior to prescribing for uses, premeds, and dosing incl. toxicity-related dose adjustments

ALL

[1 mo and older, substitute for single calaspargase pegol dose]

Dose: 25 mg/m^2/dose IM q48h x11 doses; Alt: 25 mg/m^2/dose IM x1 on Monday morning, 25 mg/m^2/dose IM x1 on Wednesday morning, 50 mg/m^2/dose IM x1 on Friday afternoon x9 total doses; Info: for pts w/ E. coli-derived asparaginase hypersensitivity; part of multi-drug chemo

[1 mo and older, substitute for single pegaspargase dose]

Dose: 25 mg/m^2/dose IM q48h x7 doses; Alt: 25 mg/m^2/dose IM x1 on Monday morning, 25 mg/m^2/dose IM x1 on Wednesday morning, 50 mg/m^2/dose IM x1 on Friday afternoon x6 total doses; Info: for pts w/ E. coli-derived asparaginase hypersensitivity; part of multi-drug chemo

lymphoblastic lymphoma

[1 mo and older, substitute for single calaspargase pegol dose]

Dose: 25 mg/m^2/dose IM q48h x11 doses; Alt: 25 mg/m^2/dose IM x1 on Monday morning, 25 mg/m^2/dose IM x1 on Wednesday morning, 50 mg/m^2/dose IM x1 on Friday afternoon x9 total doses; Info: for pts w/ E. coli-derived asparaginase hypersensitivity; part of multi-drug chemo

[1 mo and older, substitute for single pegaspargase dose]

Dose: 25 mg/m^2/dose IM q48h x7 doses; Alt: 25 mg/m^2/dose IM x1 on Monday morning, 25 mg/m^2/dose IM x1 on Wednesday morning, 50 mg/m^2/dose IM x1 on Friday afternoon x6 total doses; Info: for pts w/ E. coli-derived asparaginase hypersensitivity; part of multi-drug chemo

renal dosing

[not defined]

renal impairment: not defined

HD/PD: not defined

hepatic dosing

[not defined]